Physician profile
Ian C Herskowitz
NPI 1295880680
$18,878.57
in general payments reported to CMS, 2019-2025
60 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,331 · 2020: $743 · 2021: $2,825 · 2022: $3,229 · 2023: $3,127 · 2024: $2,694 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,720 · Education: $29.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,720.47 |
| Education | $29.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,583.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,540.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,482.38 | 2019-2025 | |
| Corcept Therapeutics | $1,116.55 | 2019-2025 | Korlym |
| Amgen INC. | $1,014.06 | 2019-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $976.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.57 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $743.36 | 2019-2023 | Farxiga |
| Abbvie INC. | $640.95 | 2019-2023 | |
| Mannkind Corporation | $614.46 | 2019-2025 | Afrezza |
| Medtronic, INC. | $599.82 | 2021-2025 | Minimed 780g |
| Antares Pharma, INC. | $583.32 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $568.46 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $561.37 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $549.98 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Herskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.